|Bioavailability||Unaffected by food|
|Elimination half-life||~20 hours|
|Chemical and physical data|
|Molar mass||426.41 g·mol−1|
|3D model (JSmol)|
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).
As of 2016[update], it is in phase III clinical trials for the treatment of asthma.
On Monday, December 16, 2019, Switzerland-based Novartis officially announced that it was jettisoning fevipiprant from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. The firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.
((cite journal)): Cite journal requires